These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37534133)

  • 1. Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in
    McCormack NM; Nguyen NY; Tully CB; Oliver T; Fiorillo AA; Heier CR
    iScience; 2023 Jul; 26(7):107161. PubMed ID: 37534133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47.
    Heier CR; McCormack NM; Tully CB; Novak JS; Newell-Stamper BL; Russell AJ; Fiorillo AA
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):940-954. PubMed ID: 36628607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models.
    Liu G; Lipari P; Mollin A; Jung S; Teplova I; Li W; Ying L; More V; Lennox W; Yeh S; McGann E; Moon YC; Rice C; Huarte E; Gruszka B; Ray B; Goodwin E; Buckendahl P; Yurkow E; Braughton B; Narasimhan J; Welch E; Voronin G; Weetall M
    Hum Mol Genet; 2024 Jan; 33(3):211-223. PubMed ID: 37819629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
    Heier CR; Yu Q; Fiorillo AA; Tully CB; Tucker A; Mazala DA; Uaesoontrachoon K; Srinivassane S; Damsker JM; Hoffman EP; Nagaraju K; Spurney CF
    Life Sci Alliance; 2019 Feb; 2(1):. PubMed ID: 30745312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone.
    Fiorillo AA; Tully CB; Damsker JM; Nagaraju K; Hoffman EP; Heier CR
    Physiol Genomics; 2018 Sep; 50(9):735-745. PubMed ID: 29883261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
    JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.
    Janghra N; Morgan JE; Sewry CA; Wilson FX; Davies KE; Muntoni F; Tinsley J
    PLoS One; 2016; 11(3):e0150818. PubMed ID: 26974331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isometric resistance training increases strength and alters histopathology of dystrophin-deficient mouse skeletal muscle.
    Lindsay A; Larson AA; Verma M; Ervasti JM; Lowe DA
    J Appl Physiol (1985); 2019 Feb; 126(2):363-375. PubMed ID: 30571283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.
    Hoffman EP
    Acta Myol; 2020 Dec; 39(4):179-186. PubMed ID: 33458572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.
    Anthony K; Cirak S; Torelli S; Tasca G; Feng L; Arechavala-Gomeza V; Armaroli A; Guglieri M; Straathof CS; Verschuuren JJ; Aartsma-Rus A; Helderman-van den Enden P; Bushby K; Straub V; Sewry C; Ferlini A; Ricci E; Morgan JE; Muntoni F
    Brain; 2011 Dec; 134(Pt 12):3547-59. PubMed ID: 22102647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy.
    Grounds MD; Lloyd EM
    J Neuromuscul Dis; 2023; 10(6):1013-1030. PubMed ID: 37927274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
    JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.
    Mavroudis PD; van den Anker J; Conklin LS; Damsker JM; Hoffman EP; Nagaraju K; Clemens PR; Jusko WJ
    J Clin Pharmacol; 2019 Jul; 59(7):979-988. PubMed ID: 30742306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit.
    Sreetama SC; Chandra G; Van der Meulen JH; Ahmad MM; Suzuki P; Bhuvanendran S; Nagaraju K; Hoffman EP; Jaiswal JK
    Mol Ther; 2018 Sep; 26(9):2231-2242. PubMed ID: 30166241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
    Conklin LS; Damsker JM; Hoffman EP; Jusko WJ; Mavroudis PD; Schwartz BD; Mengle-Gaw LJ; Smith EC; Mah JK; Guglieri M; Nevo Y; Kuntz N; McDonald CM; Tulinius M; Ryan MM; Webster R; Castro D; Finkel RS; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; McCall JM; Hathout Y; Nagaraju K; van den Anker J; Ward LM; Ahmet A; Cornish MR; Clemens PR
    Pharmacol Res; 2018 Oct; 136():140-150. PubMed ID: 30219580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.
    Vulin A; Barthélémy I; Goyenvalle A; Thibaud JL; Beley C; Griffith G; Benchaouir R; le Hir M; Unterfinger Y; Lorain S; Dreyfus P; Voit T; Carlier P; Blot S; Garcia L
    Mol Ther; 2012 Nov; 20(11):2120-33. PubMed ID: 22968479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duchenne and Becker muscular dystrophy: a molecular and immunohistochemical approach.
    Freund AA; Scola RH; Arndt RC; Lorenzoni PJ; Kay CK; Werneck LC
    Arq Neuropsiquiatr; 2007 Mar; 65(1):73-6. PubMed ID: 17420831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.